e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Pulmonary vascular diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia
A. Kratzer, J. Salys, N. Voelkel, L. Tarseviciene-Stewart (Aurora, Richmond, United States Of America)
Source:
Annual Congress 2010 - Pulmonary vascular diseases
Session:
Pulmonary vascular diseases
Session type:
Thematic Poster Session
Number:
4488
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Kratzer, J. Salys, N. Voelkel, L. Tarseviciene-Stewart (Aurora, Richmond, United States Of America). Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia. Eur Respir J 2010; 36: Suppl. 54, 4488
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Role of NFATc3 in chronic hypoxia induced pulmonary hypertension in neonatal mice
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models
Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020
Year: 2021
Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis.
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Therapeutic hypercapnia prevents pulmonary hypertension in rats with bleomycin-induced chronic neonatal lung injury
Source: Annual Congress 2011 - Resuscitation and ventilation in the baby and infant
Year: 2011
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Two rat models of hemolysis-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Systemic hypoxia contributes to pulmonary hypertension in heart failure
Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension
Year: 2011
A novel murine model of severe pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
VIP greatly attenuates monocrotaline-induced pulmonary vasculopathy in rats
Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension
Year: 2009
Precapillary pulmonary hypertension induced by aorto-caval shunt leads to a reversible bronchial hyperreactivity in rats
Source: Eur Respir J 2007; 30: Suppl. 51, 608s
Year: 2007
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept